Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib with Brentuximab or Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma
2024-520123-83-01Phase 2Authorised
- Sponsor
- University of Perugia
- Start
- Jan 2025
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of ruxolitinib, brentuximab vedotin and pembrolizumab in classical Hodgkin lymphoma (cHL) (2 cohorts), sponsored by University of Perugia. Primary endpoints: Complete response rate during or at end of ruxolitinib treatment (Cohort 1) and Complete response rate during or at end of ruxolitinib treatment (Cohort 2). Planned start Jan 2025; status: authorised.
02
Drugs
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on 2024-520123-83-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520123-83-01.